Abstract:OBJECTIVE: To investigate the effects of rosuvastatin combined with tirofiban on serum inflammatory factors and renal function in acute coronary syndrome patients with diabetes after percutaneous coronary intervention (PCI).METHODS: A total of 120 acute coronary syndrome patients with diabetes receiving PCI selected from cardiology department of our hospital during Apr. 2014-Mar. 2015 were divided into control group and observation group according to random number table, with 60 cases in each group. Except for routine treatment, control group was given Rosuvastatin calcium tablets orally after surgery (10 mg each day, for consecutive 7 d); observation group was given Rosuvastatin calcium tablets orally before and after surgery (20 mg before surgery; 10 mg each day after surgery, for consecutive 7 d), and then given Tirohydrochloric acid sodium chloride injection during surgery [10 μg/kg intravenously, 0. 15 μg/(kg· min) with intravenous pump for 36 h]. Clinical efficacies of 2 groups were compared. The changes of serum inflammatory factors (TNF-α, IL-6, IL-10) and renal function indexes (Scr, CysC, eGFR), the incidence of radiographic contrast nephropathy were compared before surgery and 24, 72 h after surgery. The occurrence of cardiovascular events was followed up for one year. RESULTS: There were no statistical significance in baseline information between 2 groups before treatment (P>0. 05). The number of complete remission case and total response rate in observation group were increased significantly higher than control group (P<0. 05), while number of invalid cases was significantly lower than control group (P<0. 05). Compared with before surgery, the levels of serum inflammation factor in 2 groups were decreased significantly 24, 72 h after surgery, while the levels of Scr and CysC were increased significantly in control group 24, 72 h after surgery and in observation group 24 h after surgery; the level of eGFR was decreased significantly, while the level of CysC was increased significantly in observation group 72 h after surgery, with statistical significance (P<0. 05). The improvement of serum inflammation factors and renal function indexes in observation group were more significant than control group (P<0. 05); the incidence of radiographic contrast nephropathy was significantly lower than control group (P<0. 05). The incidence of 1-year angina pectoris and total incidence of cardiovascular events were significantly lower than control group (P< 0. 05). CONCLUSIONS: Rosuvastatin combined with tirofiban can promote the recovery of renal function in acute coronary syndrome patients with diabetes after PCI, reduce the levels of serum inflammatory factors and decrease the incidence of radiographic contrast nephropathy and post-treatment cardiac events. Its effects are different from rosuvastatin alone.

Effect of Metformin on Acute Cardiovascular Events and Restenosis after Percutaneous Coronary Intervention in Nondiabetic Patients with Insulin Resistance

Effect of Metformin Treatment on Cardiovascular Events and Restenosis after Coronary Stenting in Patients with Impaired Glucose Tolerance Accompanied by Coronary Heart Disease

Association Between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

The Effects of Insulin Therapy on Mortality in Diabetic Patients Undergoing Percutaneous Coronary Intervention

Influence of insulin resistance on long-term outcomes in patients.

Influence of Metformin on the serum resistin concentration in patients with impaired glucose tolerance

Preventive Effects of Nicorandil and Contrast-Induced Nephropathy

The Long-Term Cardiovascular Effects of Metformin on Patients with Newly Diagnosed Type 2 Diabetes

Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction

Effects of Rosuvastatin Combined with Tirofiban on Serum Inflammatory Factors and Renal Function in Acute Coronary Syndrome Patients with Diabetes after PCI

Effects of metformin on insulin sensitivity and islet beta cell secretion in obesity patients

Association between metformin treatment and coronary artery inflammation based on pericoronary adipose tissue attenuation in type 2 diabetes mellitus patients

Long-term outcomes after stent implantation in patients with coronary atherosclerotic heart disease and diabetes mellitus

Effect of metformin on adipose tissue distribution and hepatic lipid content in patients with type 2 diabetes

Effect of insulin resistance on the vascular endothelial function in the patiens with coronary heart disease

Outcomes after Primary Coronary Intervention with Drug-Eluting Stent Implantation in Diabetic Patients with Acute St Elevation Myocardial Infarction

Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study

Protective effect of psoralidin against septic myocardial injury

Effects of Metformin on CIMT and FMD in PCOS patients: a systematic review and meta-analysis

Reversal effect and mechanism of metformin on endothelial cell dysfunction induced by intermittent high glucose